Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
This article was originally published in The Pink Sheet Daily
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.
You may also be interested in...
The J&J subsidiary has signed a deal with Boston-area Scholar Rock to discover new biologics that aim for a more pinpoint solution to inflammatory disease.
Atlas pledges to explore areas of mutual interest to the firm and its new corporate limited partners, but the drug firms won’t receive exclusive rights to anything in the new fund’s portfolio.
In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.